PRAC Reviews Depression and Anxiety Medicine Deanxit
The Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Deanxit, a fixed-dose combination medicine used for treating depression and anxiety. This review is part of the committee’s ongoing efforts to assess the safety and efficacy of medicinal products. The agenda for the PRAC meeting held from 26 to 29 October 2026 includes discussions…









